Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA NASDAQ:ANAB NASDAQ:AURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.03+1.7%$2.95$1.52▼$4.08$803.39M0.682.58 million shs1.35 million shsANABAnaptysBio$35.07+3.1%$25.52$12.21▼$35.77$981.85M-0.18581,921 shs198,351 shsAURAAura Biosciences$5.86+3.2%$6.20$4.34▼$11.35$364.02M0.45292,754 shs339,934 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.68%+3.41%+9.39%-14.89%+90.57%ANABAnaptysBio+3.15%+1.27%+58.40%+30.18%+0.92%AURAAura Biosciences+3.17%+3.35%-5.02%-18.95%-48.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.03+1.7%$2.95$1.52▼$4.08$803.39M0.682.58 million shs1.35 million shsANABAnaptysBio$35.07+3.1%$25.52$12.21▼$35.77$981.85M-0.18581,921 shs198,351 shsAURAAura Biosciences$5.86+3.2%$6.20$4.34▼$11.35$364.02M0.45292,754 shs339,934 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.68%+3.41%+9.39%-14.89%+90.57%ANABAnaptysBio+3.15%+1.27%+58.40%+30.18%+0.92%AURAAura Biosciences+3.17%+3.35%-5.02%-18.95%-48.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.71Moderate Buy$6.75122.77% UpsideANABAnaptysBio 2.67Moderate Buy$54.7856.20% UpsideAURAAura Biosciences 2.67Moderate Buy$20.50249.83% UpsideCurrent Analyst Ratings BreakdownLatest AURA, AKBA, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025AKBAAkebia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ANABAnaptysBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/15/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $70.0010/13/2025ANABAnaptysBioBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.0010/13/2025ANABAnaptysBioBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.0010/8/2025AKBAAkebia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ANABAnaptysBioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025AURAAura BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $59.009/30/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$45.009/27/2025AKBAAkebia TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M5.02N/AN/A($0.23) per share-13.17ANABAnaptysBio$91.28M10.76N/AN/A$2.33 per share15.05AURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.17N/AN/AN/A-17.91%N/A-13.47%11/6/2025 (Estimated)ANABAnaptysBio-$145.23M-$4.48N/AN/AN/A-107.66%-366.98%-30.58%11/4/2025 (Estimated)AURAAura Biosciences-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)Latest AURA, AKBA, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025AURAAura Biosciences-$0.46N/AN/AN/AN/AN/A11/6/2025Q3 2025AKBAAkebia Therapeutics-$0.02N/AN/AN/A$52.06 millionN/A11/4/2025Q3 2025ANABAnaptysBio-$1.32N/AN/AN/A$15.83 millionN/A8/13/2025Q2 2025AURAAura Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A8/6/2025Q2 2025ANABAnaptysBio-$1.50-$1.34+$0.16-$1.34$11.55 million$22.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.611.981.84ANABAnaptysBioN/A8.228.22AURAAura BiosciencesN/A12.3912.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ANABAnaptysBioN/AAURAAura Biosciences96.75%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ANABAnaptysBio33.50%AURAAura Biosciences6.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430265.14 million257.19 millionOptionableANABAnaptysBio10028.00 million18.62 millionOptionableAURAAura Biosciences5062.12 million58.21 millionNot OptionableAURA, AKBA, and ANAB HeadlinesRecent News About These CompaniesAura Biosciences (NASDAQ:AURA) CTO Sells $77,273.15 in StockOctober 17, 2025 | marketbeat.comAura Biosciences (NASDAQ:AURA) CTO Mark Plavsic Sells 12,169 SharesOctober 17, 2025 | insidertrades.comAura Biosciences (NASDAQ:AURA) Earns "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comRegency Capital Management Inc. DE Has $4.17 Million Holdings in Aura Biosciences, Inc. $AURAOctober 7, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Buy" by AnalystsOctober 3, 2025 | marketbeat.comWestern Exploration Files Amended NI 43-101 Technical Report for the AURA Gold Silver ProjectOctober 1, 2025 | newsfilecorp.comNAura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comUveal Melanoma Market Analysis Across the 7MM: Key Insights and Outlook Through 2034 | DelveInsightAugust 21, 2025 | finance.yahoo.comInsider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) SVP Sells 7,722 Shares of StockAugust 19, 2025 | insidertrades.comAura Biosciences, Inc.: Aura Biosciences Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 13, 2025 | finanznachrichten.deAura Biosciences Posts Q2 Cash SurgeAugust 13, 2025 | theglobeandmail.comAura Biosciences Reports Q2 Results and $75M FinancingAugust 13, 2025 | msn.comAura Biosciences Reports Second Quarter 2025 Financial Results and Business HighlightsAugust 13, 2025 | globenewswire.comClearside Biomedical shares dip after announcing exploration of strategic alternativesJuly 17, 2025 | msn.comJMP maintains $19 target on Aura Biosciences stock after FDA insightsMay 24, 2025 | uk.investing.comAura Biosciences, Inc. (NASDAQ:AURA) Director David Michael Johnson Acquires 20,000 SharesMay 21, 2025 | insidertrades.comAura Biosciences Raises $69.9 Million in Public OfferingMay 16, 2025 | tipranks.comAura Biosciences Names Anthony Gibney Chief Financial, Business OfficerMay 16, 2025 | marketwatch.comAura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comAura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comAura Biosciences Reports First Quarter 2025 Financial Results and Business HighlightsMay 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 2025Café Culture Revival? 3 Stocks to Watch After Chick-fil-A’s MoveBy Chris Markoch | October 9, 2025AURA, AKBA, and ANAB Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.03 +0.05 (+1.68%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.10 +0.07 (+2.31%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.AnaptysBio NASDAQ:ANAB$35.07 +1.07 (+3.15%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$35.04 -0.02 (-0.07%) As of 10/24/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Aura Biosciences NASDAQ:AURA$5.86 +0.18 (+3.17%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.95 +0.09 (+1.54%) As of 10/24/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
